Supplementary Table 4.MMC placement subanalysis: Patient demographics and baseline characteristics of patients who underwent MicroShunt implantation (PP population).

|  |  |  |
| --- | --- | --- |
| Variable | Group 1 (*n* = 36) | Group 2 (*n* = 25) |
| Mean age ± SD, years | 61.7 ± 14.1 | 67.5 ± 11.6 |
| Male, *n* (%) | 20 (55.6) | 15 (60.0) |
| Lens status, *n* (%) |  |  |
| Phakic | 18 (50.0) | 15 (60.0) |
| Pseudophakic | 18 (50.0) | 10 (40.0) |
| Mean IOP ± SD, mmHg | 26.1 ± 6.5 | 25.0 ± 5.5 |
| IOP ≥18 and ≤21 mmHg, *n* (%) | 11 (30.6) | 8 (32.0) |
| IOP >21 mmHg, *n* (%) | 25 (69.4) | 17 (68.0) |
| Mean number of glaucoma medications ± SD | 3.1 ± 1.0 | 2.6 ± 1.3 |
| Mean VA ± SD, logMAR | 0.35 ± 0.70 | 0.18 ± 0.24 |

Group 1 was defined as the first 36 patients to undergo MicroShunt implantation, and Group 2 as the following 25 patients to receive MicroShunt.

IOP, intraocular pressure; MMC, Mitomycin C; PP, per-protocol; SD, standard deviation; VA, visual acuity.